Eam Investors, LLC Arcellx, Inc. Transaction History

Eam Investors, LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	BUY	$51.85 - $73.49 $51,850 - $73,490	1,000 Added 1.54%	66,052 $4.59 Million
Q4 2023 Feb 13, 2024	BUY	$31.75 - $57.99 $2.07 Million - $3.77 Million	65,052 New	65,052 $3.61 Million
Q2 2023 Aug 11, 2023	SELL	$27.49 - $46.9 $1.34 Million - $2.28 Million	-48,587 Reduced 46.58%	55,714 $1.76 Million
Q1 2023 Jul 12, 2023	BUY	$26.92 - $33.94 $2.7 Million - $3.41 Million	100,426 Added 2591.64%	104,301 $3.21 Million
Q1 2023 May 12, 2023	SELL	$26.92 - $33.94 $3.36 Million - $4.23 Million	-124,650 Reduced 96.99%	3,875 $119,000
Q4 2022 Feb 14, 2023	SELL	$17.18 - $33.0 $13,073 - $25,113	-761 Reduced 0.59%	128,525 $3.98 Million
Q3 2022 Nov 14, 2022	SELL	$16.67 - $22.04 $25,405 - $33,588	-1,524 Reduced 1.17%	129,286 $2.43 Million
Q2 2022 Aug 12, 2022	BUY	$7.21 - $24.43 $943,140 - $3.2 Million	130,810 New	130,810 $2.37 Million

210

44.2M

2.23M

907K

Ticker ACLX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,819,200
Market Cap $2.93B
Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It...

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Investors, LLC with notifications on news.